Amicus Therapeutics, Inc. (FRA:AM6)
8.30
+0.05 (0.61%)
At close: Dec 4, 2025
Amicus Therapeutics Revenue
Amicus Therapeutics had revenue of $169.06M USD in the quarter ending September 30, 2025, with 19.46% growth. This brings the company's revenue in the last twelve months to $598.70M, up 21.28% year-over-year. In the year 2024, Amicus Therapeutics had annual revenue of $528.30M with 32.29% growth.
Revenue (ttm)
$598.70M
Revenue Growth
+21.28%
P/S Ratio
5.15
Revenue / Employee
$1.20M
Employees
499
Market Cap
2.63B EUR
Revenue Chart
* This company reports financials in USD.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 528.30M | 128.94M | 32.29% |
| Dec 31, 2023 | 399.36M | 70.12M | 21.30% |
| Dec 31, 2022 | 329.23M | 23.72M | 7.76% |
| Dec 31, 2021 | 305.51M | 44.63M | 17.11% |
| Dec 31, 2020 | 260.89M | 78.65M | 43.16% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| SAP SE | 36.49B |
| Siemens Aktiengesellschaft | 78.91B |
| Allianz SE | 105.02B |
| Deutsche Telekom AG | 121.02B |
| Siemens Energy AG | 39.08B |
| Rheinmetall AG | 11.00B |
| Münchener Rückversicherungs-Gesellschaft Aktiengesellschaft in München | 62.10B |
| Deutsche Bank Aktiengesellschaft | 29.86B |
Amicus Therapeutics News
- 9 days ago - Insider Sell Alert: David Clark Sells 25,643 Shares of Amicus Therapeutics Inc (FOLD) - GuruFocus
- 13 days ago - Ireland scores Trump tariff win as US drug-maker moves rare medicine production from China to avoid trade levies - Independent Ireland
- 24 days ago - Amicus Therapeutics: Moving Towards Consistent Profitability - Seeking Alpha
- 25 days ago - Amicus Therapeutics, Inc. (FOLD) Presents at UBS Global Healthcare Conference 2025 Transcript - Seeking Alpha
- 25 days ago - Wall Street Analysts Believe Amicus Therapeutics (FOLD) Could Rally 76.32%: Here's is How to Trade - Nasdaq
- 4 weeks ago - Bet on These 4 Top-Performing Liquid Stocks to Maximize Returns - Nasdaq
- 4 weeks ago - JP Morgan Raises Price Target for Amicus Therapeutics (FOLD) to $19 | FOLD Stock News - GuruFocus
- 4 weeks ago - Insider Sell: David Clark Sells Shares of Amicus Therapeutics Inc (FOLD) - GuruFocus